La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cardiol Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cardiol Therapeutics..

Cardiol Therapeutics (NASDAQ:CRDL) Azioni, Catena delle Opzioni

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Press Releases

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

CRDL

TSX:CRDL

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Vyome Holdings

ImageneBio

Intercure

Incannex Healthcare

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Cassava Sciences

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

Turn Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Cardiol Therapeutics

Cardiol Therapeutics (CRDL) Opzioni

Cardiol Therapeutics (NASDAQ:CRDL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO